NCT02903836 - Phase II Study of Oral Nafithromycin in CABP | Biotech Hunter

Enrollment

231

Participants

Timeline

Start Date

November 18, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 8, 2017

Conditions

Community-Acquired Bacterial Pneumonia (CABP)

Interventions

DRUG

Nafithromycin 800 mg 3 days

DRUG

Nafithromycin 800 mg 5 days

DRUG

Moxifloxacin 400 mg

Trial Locations (6)

Empire Clinical Research, LLC, Miami Lakes

A & L Clinical research, Miami

A Plus Research Inc., Miami

RM Medical Research, Inc., Miami

Health Concepts, Bedford

HCI Metromedic Walkin Medical Center, Bedford